Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic and Subtenon Chemotherapy for Retinoblastoma
NCT00072384Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2007
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of carboplatin, vincristine sulfate liposome injection and etoposide in retinoblastoma (Rb), sponsored by Children's Oncology Group. Primary endpoints: Group D Eyes - Treatment Failure Within One Year at 1 year and Group C Eyes - Treatment Failure Within One Year at 1 year. Started Apr 2007; status: completed.
02
Drugs
carboplatinvincristine sulfate liposome injectionetoposide
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT00072384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072384.